Valuation dashboard for Corcept Therapeutics Incorporated (CORT) with P/E 207.35, P/B 16.10, EV/EBITDA 412.58 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily.
Analysis Summary
Corcept Therapeutics Incorporated reported revenue of $761.4M in the most recent fiscal year, growing at a 5-year CAGR of 16.6%. Net income reached $99.7M, with a -1.2% 5-year CAGR.
Trailing-twelve-month margins: gross margin 98.3%, operating margin 0.8%, net margin 6.6%.
At the current price of $111.81, CORT trades at a P/E of 207.35 and an ROE of 8.37%. Market capitalisation stands at $12.1B, placing it among large-cap names.
Balance sheet quality for CORT: current ratio of 2.9. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 207.35 |
| Price / Book | 16.10 |
| EV / EBITDA | 412.58 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $54.42 |
| vs Current Price | -51.3% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CORT | Corcept Therapeutics Incorporated | $12.1B | 207.35 | 16.10 | 8.4% |
| JAZZ | Jazz Pharmaceuticals plc | $15.5B | 15.84 | 3.17 | 21.4% |
| AXSM | Axsome Therapeutics, Inc. | $10.9B | |||
| ABVX | Abivax S.A. | $7.5B | 15.11 | -73.9% | |
| HALO | Halozyme Therapeutics, Inc. | $12.7B | 30.18 | 86.81 | |
| CYTK | Cytokinetics, Incorporated | $9.1B | 119.0% | ||
| NUVL | Nuvalent, Inc. | $9.1B | 8.30 | ||
| CAI | Caris Life Sciences, Inc. | $8.0B | 85.99 | 15.29 | 18.8% |
Price
| Price | $111.81 |
| Market Cap | $12.1B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 8.37% |
| Return on Invested Capital | 0.87% |
| Return on Assets | 6.18% |
| Gross Margin | 98.30% |
| Operating Margin | 0.77% |
| Net Margin | 6.61% |
Related companies: ABVX · AXSM · CAI · CYTK · HALO · JAZZ · MRUS
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of CORT: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks